https://www.sttinfo.fi/tiedote/72370478/zasocitinib-delivered-superior-efficacy-versus-deucravacitinib-in-new-phase-3-head-to-head-results-reinforcing-potential-to-deliver-rapid-and-durable-skin-clearance-in-a-convenient-once-daily-pill?publisherId=58763726&lang=en
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results,...
Takeda (TSE:4502/NYSE:TAK) announced new data from threePhase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation,...
zasocitinibdeliveredsuperiorefficacyversus
https://www.sotyktu.com/psoriatic-arthritis/about-sotyktu/sotyktu-study-results
Psoriatic Arthritis (PsA) Study Results - SOTYKTU® (deucravacitinib)
View clinical trial results comparing SOTYKTU® (deucravacitinib) to placebo, and see how adults with psoriatic arthritis found relief. Please see Indication...
psoriatic arthritispsastudyresultsdeucravacitinib
https://www.esgi-infrastructure.eu/shop/b8781-50-deucravacitinib-50mg-47145
Deucravacitinib - 50mg | ESGI infrastructure
deucravacitinibesgiinfrastructure